

**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

Receipt date: 09/16/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

/T.V./	1	SCHEFFER ET AL., "The drug resistance-related protein LRP is the human major vault protein" Nat. Med. 1:578-582 (1995). <input type="checkbox"/>
	2	SCHERR ET AL., "Quantitative Determination of Lentiviral Vector Particle Numbers by Real-time PCR" BioTechniques 31:520-526 (2001). <input type="checkbox"/>
	3	SCHLINGENSIEPEN ET AL., Blackwell Science Ltd., Vol. 6, 1997, "Antisense - From Technology to Therapy". <input type="checkbox"/>
	4	SECRIST ET AL., Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleotides, Nucleotides and their Biological Applications, Park City, Utah, Sep, 16-20 (1992). <input type="checkbox"/>
	5	SHANNON ET AL., "Modeling myeloid leukemia tumors suppressor gene inactivation in the mouse" Semin. Cancer Biol. 11:191-199 (2001). <input type="checkbox"/>
	6	SHEA ET AL., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates" Nucl. Acids Res. 18:3777-3783 (1990). <input type="checkbox"/>
	7	SKORSKI ET AL., "Suppression of Philadelphia Leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide" Proc. Natl. Acad. Sci. USA 91:4504-4508 (1994). <input type="checkbox"/>
	8	STETLER-STEVENSON ET AL., "Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis" Annu. Rev. Cell Biol. 9:541-573 (1993). <input type="checkbox"/>
	9	STRASSER ET AL., "Apoptosis Signaling" Annu. Rev. Biochem. 69:217-245 (2000). <input type="checkbox"/>
	10	SVINARCHUK ET AL., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups" Biochimie 75:49-54 (1993). <input type="checkbox"/>
↓	11	THOMSON ET AL., "Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications" J. Org. Chem. 61:6273-6281 (1996). <input type="checkbox"/>

Receipt date: 09/16/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

/T.V./	12	MARTINEZ ET AL., "Single stranded antisense siRNAs guide target RNA cleavage in RNAi," Cell, 110:563-574 (2002).	<input type="checkbox"/>
	13	VAN BEUSECHEM ET AL., "Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells" Proc. Natl. Acad. Sci. USA 89:7640-7644 (1992).	<input type="checkbox"/>
	14	VAN ETTE, "Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models" Curr. Opin. Hematol. 8:224-230 (2001).	<input type="checkbox"/>
	15	VICKERS ET AL., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A COMPARATIVE ANALYSIS" J. Biol. Chem. 278: 7108-7118 (2003).	<input type="checkbox"/>
	16	WACHECK ET AL., "Small Interfering RNA Targeting Bcl-2 Sensitizers Malignant Melanoma" Oligonucleotides, Vol. 13 (5):393-400 (2003).	<input type="checkbox"/>
	17	WAGNER, "The state of the art in antisense research" Nat. Med. 1:1116-1118 (1995).	<input type="checkbox"/>
	18	WILLIAMS ET AL., "Thermodynamic Comparison of the Salt Dependence of Natural RNA Hairpins and RNA Hairpins with Non-Nucleotide Spacers" Biochemistry 35:14665-14670 (1996).	<input type="checkbox"/>
	19	WILSON ET AL., "Retrovirus-mediated transduction of adult hepatocytes" Proc. Natl. Acad. Sci. USA 85:3014-3018 (1988).	<input type="checkbox"/>
	20	WINK, Molekulare Biotechnologie, Wiley-VCH, 2004, 557-577.	<input type="checkbox"/>
	21	WONG ET AL., "Modeling Philadelphia chromosome positive leukemias" Oncogene 20:5644-5659 (2001).	<input type="checkbox"/>
↓	22	YOKOTA, "Tumor progression and metastasis" Carcinogenesis 21:497-503 (2000).	<input type="checkbox"/>

Receipt date: 09/16/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

/T.V./	23	ZAMORE ET AL., "Evidence that siRNAs function as guides not primers in the drosophila and human RNAi pathways," Mol. Cell, 10:537-48 (2002).	<input type="checkbox"/>
	24	ZENG ET AL., "The Fetal Origin of B-Precursor Leukemia in the Eu-ret Mouse" Blood 92:3529-3536 (1988).	<input type="checkbox"/>
	25	AGRAWAL ET AL., "Antisense therapeutics: is it as simple as complementary base recognition," Molecular Medicine, 6:72-81 (2000).	<input type="checkbox"/>
	26	ALFONZO ET AL., "The mechanism of U insertion/deletion RNA editing in kinetoplastid mitochondria," Nucleic Acid Research, 25:3751-3759 (1997).	<input type="checkbox"/>
	27	ANDERSON, "Human Gene Therapy," Nature, 392:25-30 (1998).	<input type="checkbox"/>
	28	BRANCH, "A good antisense molecule is hard to find," TIBS, 23:45-50 (1998).	<input type="checkbox"/>
	29	DOLINNAYA, N.G. ET AL., "Oligonucleotide circularization by template-directed chemical ligation," Nucleic Acids Research, 21:5403-5407 (1993).	<input type="checkbox"/>
	30	EXPERT-BEZANCON, A. ET AL., "Precise localization of several covalent RNA-RNA cross-link in Escherichia coli 16S RNA," European Journal of Biochemistry, 136:267-274 (1983).	<input type="checkbox"/>
	31	FIRE, A. ET AL., "Specific interference by ingested dsRNA," Nature, 395:854 (1998).	<input type="checkbox"/>
	32	GAO H., ET AL., "Circularization of oligonucleotides by disulfide bridge formation," Nucleic Acids Research, 23:2025-2029 (1995).	<input type="checkbox"/>
↓	33	JASCHKE, ET AL., "Synthesis and analytical characterization of RNA polyethylene glycol conjugates," Nucleosides & Nucleotides, 15:1519-1529 (1996).	<input type="checkbox"/>

Receipt date: 09/16/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

/T.V./	34	KAUFMAN, R.J., ET AL., "Double-stranded RNA-activated protein kinase mediates virus -induced apoptosis: A new role for an old actor," PNAS USA, 96:11693-11695 (1999). <input type="checkbox"/>
	35	LIPSON, S.E., ET AL., "Psoralen cross-linking of ribosomal RNA," Methods in Enzymology, 164:330-341 (1988). <input type="checkbox"/>
	36	LIU, Z. R., ET AL., "Detection of a novel ATP-dependent cross-linked protein at the 5' splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking, Molecular Cell Biology, 18:6910-6920 (1998). <input type="checkbox"/>
	37	MICURA, R. "Cyclic oligoribonucleotides (RNA) by solid-phase synthesis," Chem. Eur. J., 5:2077-2082 (1999). <input type="checkbox"/>
	38	RAVINDERJIT ET AL., "Regiospecific Solid-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2',5'- (or 2',3')- and 3',5'-Phosphodiester Linkages on the Formation of Hairpin DNA," Bioconjugate Chemistry, 8:370-377 (1997). <input type="checkbox"/>
	39	ROSALIND, C. L., ET AL., "The C. elegans Herochronic Gene lin-4 encodes small RNAs with antisense complementary to lin-14," Cell, 75:843-854 (1993). <input type="checkbox"/>
	40	SEYDOUX, G., ET AL., "Repression of gene expression in the embryonic germ lineage of C. elegans," Nature 382:713-716 (1996). <input type="checkbox"/>
	41	THOMPSON, J. D., "Shortcuts from gene sequence to function," Nature Biotechnology, 17:1158-1159 (1999). <input type="checkbox"/>
	42	VERMA, ET AL., "Gene therapy - promises, problems, and prospects," Nature, 389:239-242 (1997). <input type="checkbox"/>
	43	WAGNER, ET AL., "Double-stranded RNA poses puzzle," Nature, 391:744-745 (1998). <input type="checkbox"/>
↓	44	WANG, S., ET AL., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs," Nucleic Acids Research, 22:2326-2333 (1994). <input type="checkbox"/>

Receipt date: 09/16/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

/T.V./	45	WANG, Z. ET AL., "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking," Biochem., 35:6491-6499 (1996). <input type="checkbox"/>
	46	WATKINS, K. P., ET AL., "In vivo UV cross-linking of U snRNAs that participate in trypanosome trans-splicing," Genes & Development, 5:1859-1869 (1991). <input type="checkbox"/>
	47	WENGEL, J., "Synthesis of 3'-C- and 4'-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)," Acc. Chem. Res., 32:301-310 (1999). <input type="checkbox"/>
↓	48	ZWIEB, C. ET AL., "Evidence for RNA-RNA cross-linked formation in Escherichia coli ribosomes," Nucleic Acids Research, 5:2705-2720 (1978). <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Tracy Vivlemore/	Date Considered	04/24/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.